Physician profile
Daniel P Ikeda
NPI 1730124520
$6,664.93
in general payments reported to CMS, 2019-2025
45 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 82% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $596 · 2021: $1,113 · 2022: $929 · 2023: $900 · 2024: $748 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.65 |
| Education | $223.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $842.97 | 2019-2025 | Trelegy Ellipta, Nucala |
| Merck Sharp & Dohme LLC | $710.99 | 2019-2025 | Pifeltro, Zerbaxa, Delstrigo |
| Astrazeneca Pharmaceuticals Lp | $441.27 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.59 | 2019-2024 | Ofev, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $335.07 | 2019-2025 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $316.38 | 2019-2023 | |
| Allergan, INC. | $246.67 | 2019-2020 | |
| Astellas Pharma US INC | $240.88 | 2023-2025 | Ambisome, Cresemba |
| Insmed, INC. | $237.44 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $166.17 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Ethicon US, LLC | $149.76 | 2025 | Evarrest |
| Grifols USA, LLC | $137.45 | 2020-2023 | Prolastin-C Liquid |
| Alcresta Therapeutics, INC. | $123.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $95.66 | 2022-2025 | Dupixent |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ikeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.